The World Health Organization has unveiled critical updates to the influenza vaccine for the 2026-2027 northern hemisphere season, fully refreshing all strains to counter the rapid spread of the new A(H3N2) subclade K variant and...
Eli Lilly's tirzepatide holds premium pricing in India ahead of March 2026 generics rush. With explosive sales and stronger efficacy than competitors, the company sees room for both branded and low-cost options.
Zydus Lifesciences has received final USFDA approval for its Ivermectin Tablets 3 mg and Dapsone Tablets 25 mg and 100 mg, further expanding its global pharmaceutical footprint.
Eli Lilly and Company reported that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior blood sugar control and weight loss compared with oral semaglutide in a head-to-head phase 3 trial in adults with type 2 diabet...
CDSCO now allows companies to begin lab testing of new drugs immediately after filing applications. The move aims to speed approvals for manufacturing or importing drugs while keeping technical scrutiny for later stages.
Sanofi Consumer Healthcare India has posted impressive financial results for Q4’25, with a 50% jump in profit after tax (PAT) and a 47% rise in revenue. For the full year, the company achieved a 21% growth in revenue, delivering strong performance ac
Eli Lilly and Company (India) has launched the next phase of its obesity awareness campaign, using films led by well-known personalities to shift the focus from blame to science and encourage doctor-led care.
Lupin Limited has ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment, scoring 91 out of 100 and emerging as the top pharmaceutical company worldwide.
Alembic Pharma has received USFDA approval for its generic Lamotrigine Orally Disintegrating Tablets in multiple strengths, boosting its presence in the US generics market and expanding its epilepsy treatment portfolio.
Boehringer Ingelheim has received FDA approval for its drug Ofev as a first-line treatment for non-small cell lung cancer. The approval offers a new option for patients with metastatic NSCLC, combining Ofev with chemotherapy for better outcomes.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")